New Drug Shows Potential for Treating Lymphoedema
A small preliminary study suggests this medication could reduce limb swelling in adults with lymphoedema.
Updated on Oct. 24, 2026 in Weight Loss
Live Poll
Do you believe medical research should focus more on new drug treatments for chronic conditions?
A preliminary clinical trial suggests that the drug acebilustat may help reduce limb swelling and inflammation in patients with lymphoedema. The small study indicates potential benefits for the condition, though the drug is not yet approved for this use in the U.S. or U.K.
Why it matters
Lymphoedema currently lacks pharmaceutical treatments, making this study a notable step in exploring potential medication-based symptom management. The findings remain preliminary and require further validation in larger, controlled clinical settings.
This preliminary clinical trial followed 23 participants over a 12-month period. While researchers observed an average 5 percent reduction in limb swelling, the trial lacked a control group for comparison.
The players
Lauren Scheidegger
A 34-year-old participant in the acebilustat clinical trial.
Debon Cochrane
A 62-year-old participant in the clinical trial who previously underwent ovarian cancer surgery in 1999.
The details
Acebilustat works by blocking the leukotriene B4 (LTB4) molecule, which is thought to drive chronic tissue inflammation in patients with lymphoedema. By inhibiting this molecule, the daily medication aims to reduce the fluid retention and swelling characteristic of the condition. Researchers noted that some participants reported persistent symptom relief even after ceasing the treatment.
Timeline
Participants underwent a 12-month clinical trial period.
Debon Cochrane underwent surgery for ovarian cancer in 1999.
Health Landscape
The study marks an early effort to shift from standard mechanical management to targeted pharmaceutical treatments for lymphoedema. It builds upon a broader scientific search for therapies that address the underlying inflammatory drivers of chronic lymphatic fluid accumulation.
Because this drug is not currently approved for lymphoedema, patients should continue their established care routines and avoid seeking this medication outside of clinical settings. If you are interested in experimental therapies, discuss current, reputable clinical trial registries with your physician.
The takeaway
While these initial findings regarding acebilustat are promising, the lack of a control group means the results are currently limited in scope. Readers should focus on maintaining existing, physician-directed compression and self-care protocols for managing lymphoedema symptoms.
Further reading
For more on managing long-term fluid conditions, visit our Weight Loss section.
Source note: This article includes information reported by Mail Online.
Live Poll
Do you believe medical research should focus more on new drug treatments for chronic conditions?
